Inosine

• INDICATION AND USAGE Rejuvesol ® Solution is intended only to be used as an in vitro processing solution for the rejuvenation of a unit of RBC. RBC may be rejuvenated after storage in CPD (non-leukocyte reduced), CPDA-1, (non-leukocyte reduced), CPD/ADSOL ® (CPD/AS-1 leukocyte reduced), or CP2D/Nutricel ® (CP2D/AS-3, leukocyte reduced).

AND CONTRAINDICATIONS Rejuvesol ® Solution is intended only for the extracorporeal rejuvenation of a RBC. It should never be directly administered to Humans. Rejuvesol ® Solution must not be added to whole blood because the additional plasma may reduce the effectiveness of the rejuvenation process. Immediately after rejuvenation, RBC must either be washed via an approved protocol prior to transfusion or glycerolized and frozen. RBC which have been rejuvenated, glycerolized, and frozen must be deglycerolized via an approved protocol prior to transfusion. RBC rejuvenated before 6 days of storage may achieve 2,3-DPG levels in excess of 2 times normal and ATP levels in excess of 1.5 times normal. 5,6 In patients with reduced arterial blood p0 2 of less than 40 torr, the use of RBC rejuvenated before 6 days of storage are contraindicated because their high 2,3-DPG levels and low oxygen affinity may impair proper oxygenation of the red blood cells in the lung. 7 Rejuvenated RBC are further processed prior to transfusion to remove the un-used portion of rejuvesol ® Solution, by-products of the rejuvenation process, and any other potential storage-related impurities in rejuvesol ® Solution. Based on the concentration of the residual inosine in rejuvenated RBC that are either washed or deglycerolized, the average washout of inosine was calculated to be > 97.4%. A literature search for potential toxicity associated with the ingredients that comprise rejuvesol ® Solution, including potential metabolites, was conducted.

Recent PubMed references pinned to Inosine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Inosine Ameliorates the Injurious Microenvironment for Oligodendrocyte Precursor Cells by Suppressing Microglial Activation and Neuroinflammation In Vitro.
  Neurochemical research · 2026 · Han Y, Chen J, Wang P, et al.
  PMID 42159816DOI 10.1007/s11064-026-04771-1
• Metabolic and Genetic Alterations in Early and Exudative Age-Related Macular Degeneration: Inosine, Amino Acids, and COL2A1 Gene Variant.
  International journal of molecular sciences · 2026 · Bruzaite A, Vilkeviciute-Petraite A, Cebatoriene D, et al.
  PMID 42074336DOI 10.3390/ijms27083697
• MULTIMODAL IMAGING OF DIDANOSINE-RELATED RETINOPATHY.
  Retinal cases & brief reports · 2025 · Alexander JG, Samico GA, Ribeiro LZ, et al.
  PMID 41995410DOI 10.1097/ICB.0000000000001625
• Structural and functional analysis of the Bacillus cereus GerI inosine-responsive spore germinant receptor.
  mBio · 2026 · Li Y, Ow-Young-Villarreal G, Pustovalova Y, et al.
  PMID 41891750DOI 10.1128/mbio.00108-26
• Inosine alleviates colorectal cancer liver metastasis by promoting M1 macrophage polarization and modulating the PI3K/AKT signaling pathway.
  Frontiers in immunology · 2026 · Dong Y, Ma Y, Yu Q, et al.
  PMID 41890717DOI 10.3389/fimmu.2026.1780972
• Dynamic A-to-I RNA editing in response to gut microbiome in honey bees.
  Genome research · 2026 · Duan Y, Huang M, Ye L, et al.
  PMID 41781334DOI 10.1101/gr.280291.124
• Adenosine-to-Inosine (A-to-I) RNA Editing by ADAR1 to Control RNA Sensing in Cardiovascular Disease.
  Arteriosclerosis, thrombosis, and vascular biology · 2026 · Weldy CS, Li JB, Quertermous T, et al.
  PMID 41744067DOI 10.1161/ATVBAHA.125.323847
• Erythropoiesis-inosine metabolic axis failure underlying retinal neurodegeneration in glaucoma: novel diagnoses and therapies.
  Experimental & molecular medicine · 2026 · Chou Y, Liu W, Li Y, et al.
  PMID 41688739DOI 10.1038/s12276-026-01654-x

The 10 most recently updated of 228 ClinicalTrials.gov registrations naming Inosine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
  Recruiting · Phase 1 · Interventional · 570 enrolled · Sanofi
  NCT07516418updated 2026-05-08
• Outpatient Induction of Labour Using a Double Balloon Transcervical Catheter in Low-risk Pregnant Women: a Two-centre Open Prospective Randomised Controlled Trial - OutCRIB
  Recruiting · Interventional · 258 enrolled · Nantes University Hospital
  NCT07265518updated 2026-05-07
• Effect of a Health Pathway for People With Persistent Symptoms Covid-19
  Active not recruiting · Interventional · 400 enrolled · Centre Hospitalier Universitaire de Saint Etienne
  NCT05787366updated 2026-05-06
• Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice
  Completed · Observational · 286 enrolled · POLYSAN Scientific & Technological Pharmaceutical Company
  NCT05928286updated 2026-04-21
• Cytoflavin in the Complex Rehabilitation of Stroke Patients
  Completed · Phase 3 · Interventional · 240 enrolled · POLYSAN Scientific & Technological Pharmaceutical Company
  NCT05935787updated 2026-04-14
• Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
  Enrolling by invitation · Observational · 178 enrolled · AvenCell Therapeutics, Inc.
  NCT07474051updated 2026-03-16
• Immune Defense Protein Impact On Respiratory Immune Outcomes
  Recruiting · Interventional · 300 enrolled · Quantec Ltd
  NCT07431840updated 2026-03-12
• De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia
  Recruiting · Phase 4 · Interventional · 600 enrolled · The University of Texas Health Science Center, Houston
  NCT05213676updated 2026-02-09
• Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
  Completed · Observational · 33 enrolled · University Hospital, Bordeaux
  NCT06444477updated 2026-01-26
• Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
  Terminated · Phase 1 · Interventional · 32 enrolled · AvenCell Europe GmbH
  NCT04230265updated 2026-01-22

Frequently asked questions

What is Inosine used for?

According to FDA labeling, Inosine carries indications including: INDICATION AND USAGE Rejuvesol ® Solution is intended only to be used as an in vitro processing solution for the rejuvenation of a unit of RBC. RBC may be rejuvenated after storage in CPD (non-leukocyte reduced), CPDA-1, (non-leukocyte reduced), CPD/ADSOL ® (CPD/AS-1 leukocyte reduced), or CP2D/Nutricel ® (CP2D/AS-3, leukocyte reduced).. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Inosine?

Inosine is classified as Antivirals, Other antiinfectives and antiseptics, Other ophthalmologicals.